Clinical Trials Logo

Giant Cell Tumor of Bone clinical trials

View clinical trials related to Giant Cell Tumor of Bone.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04255576 Active, not recruiting - Clinical trials for Giant Cell Tumor of Bone

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Start date: October 10, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of JMT103 in patients with surgically unsalvageable or refractory giant cell tumor of bone (GCTB).

NCT ID: NCT03449108 Active, not recruiting - Clinical trials for Triple Negative Breast Cancer

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. LN-145-S1 is made using a modified process that chooses a specific portion of the T-cells. The T cells may specifically recognize, target, and kill the tumor cells.